96 related articles for article (PubMed ID: 9369498)
1. Human recombinant phosphodiesterase 4B2B binds (R)-rolipram at a single site with two affinities.
Rocque WJ; Tian G; Wiseman JS; Holmes WD; Zajac-Thompson I; Willard DH; Patel IR; Wisely GB; Clay WC; Kadwell SH; Hoffman CR; Luther MA
Biochemistry; 1997 Nov; 36(46):14250-61. PubMed ID: 9369498
[TBL] [Abstract][Full Text] [Related]
2. Detailed characterization of a purified type 4 phosphodiesterase, HSPDE4B2B: differentiation of high- and low-affinity (R)-rolipram binding.
Rocque WJ; Holmes WD; Patel IR; Dougherty RW; Ittoop O; Overton L; Hoffman CR; Wisely GB; Willard DH; Luther MA
Protein Expr Purif; 1997 Mar; 9(2):191-202. PubMed ID: 9056484
[TBL] [Abstract][Full Text] [Related]
3. Dual inhibition of human type 4 phosphodiesterase isostates by (R, R)-(+/-)-methyl 3-acetyl-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-3- methyl-1-pyrrolidinecarboxylate.
Tian G; Rocque WJ; Wiseman JS; Thompson IZ; Holmes WD; Domanico PL; Stafford JA; Feldman PL; Luther MA
Biochemistry; 1998 May; 37(19):6894-904. PubMed ID: 9578576
[TBL] [Abstract][Full Text] [Related]
4. Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding.
Jacobitz S; McLaughlin MM; Livi GP; Burman M; Torphy TJ
Mol Pharmacol; 1996 Oct; 50(4):891-9. PubMed ID: 8863835
[TBL] [Abstract][Full Text] [Related]
5. CDP840: a novel inhibitor of PDE-4.
Perry MJ; O'Connell J; Walker C; Crabbe T; Baldock D; Russell A; Lumb S; Huang Z; Howat D; Allen R; Merriman M; Walls J; Daniel T; Hughes B; Laliberte F; Higgs GA; Owens RJ
Cell Biochem Biophys; 1998; 29(1-2):113-32. PubMed ID: 9631241
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site.
Barnette MS; Grous M; Cieslinski LB; Burman M; Christensen SB; Torphy TJ
J Pharmacol Exp Ther; 1995 Jun; 273(3):1396-402. PubMed ID: 7791113
[TBL] [Abstract][Full Text] [Related]
7. Inhibitor binding to type 4 phosphodiesterase (PDE4) assessed using [3H]piclamilast and [3H]rolipram.
Zhao Y; Zhang HT; O'Donnell JM
J Pharmacol Exp Ther; 2003 May; 305(2):565-72. PubMed ID: 12704225
[TBL] [Abstract][Full Text] [Related]
8. Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast.
Torphy TJ; Stadel JM; Burman M; Cieslinski LB; McLaughlin MM; White JR; Livi GP
J Biol Chem; 1992 Jan; 267(3):1798-804. PubMed ID: 1309798
[TBL] [Abstract][Full Text] [Related]
9. Functional and biochemical evidence for diazepam as a cyclic nucleotide phosphodiesterase type 4 inhibitor.
Collado MC; Beleta J; Martinez E; Miralpeix M; Domènech T; Palacios JM; Hernández J
Br J Pharmacol; 1998 Mar; 123(6):1047-54. PubMed ID: 9559885
[TBL] [Abstract][Full Text] [Related]
10. Behaviour of [11C]R(-)- and [11C]S(+)-rolipram in vitro and in vivo, and their use as PET radiotracers for the quantificative assay of PDE4.
Parker CA; Matthews JC; Gunn RN; Martarello L; Cunningham VJ; Dommett D; Knibb ST; Bender D; Jakobsen S; Brown J; Gee AD
Synapse; 2005 Mar; 55(4):270-9. PubMed ID: 15668983
[TBL] [Abstract][Full Text] [Related]
11. Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret.
Duplantier AJ; Biggers MS; Chambers RJ; Cheng JB; Cooper K; Damon DB; Eggler JF; Kraus KG; Marfat A; Masamune H; Pillar JS; Shirley JT; Umland JP; Watson JW
J Med Chem; 1996 Jan; 39(1):120-5. PubMed ID: 8568798
[TBL] [Abstract][Full Text] [Related]
12. A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.
Blount MA; Zoraghi R; Ke H; Bessay EP; Corbin JD; Francis SH
Mol Pharmacol; 2006 Nov; 70(5):1822-31. PubMed ID: 16926278
[TBL] [Abstract][Full Text] [Related]
13. Characterization of CHO-K1 cells stably expressing PDE-IV enzymes. Whole-cell cAMP determinations vs broken-cell enzymatic assays.
Pon DJ; Plant M; Tkach J; Boulet L; Muise E; Allen RA; Rodger IW
Cell Biochem Biophys; 1998; 29(1-2):159-78. PubMed ID: 9631244
[TBL] [Abstract][Full Text] [Related]
14. PDE4B5, a novel, super-short, brain-specific cAMP phosphodiesterase-4 variant whose isoform-specifying N-terminal region is identical to that of cAMP phosphodiesterase-4D6 (PDE4D6).
Cheung YF; Kan Z; Garrett-Engele P; Gall I; Murdoch H; Baillie GS; Camargo LM; Johnson JM; Houslay MD; Castle JC
J Pharmacol Exp Ther; 2007 Aug; 322(2):600-9. PubMed ID: 17519386
[TBL] [Abstract][Full Text] [Related]
15. Characterization of two recombinant PDE3 (cGMP-inhibited cyclic nucleotide phosphodiesterase) isoforms, RcGIP1 and HcGIP2, expressed in NIH 3006 murine fibroblasts and Sf9 insect cells.
Leroy MJ; Degerman E; Taira M; Murata T; Wang LH; Movsesian MA; Meacci E; Manganiello VC
Biochemistry; 1996 Aug; 35(31):10194-202. PubMed ID: 8756484
[TBL] [Abstract][Full Text] [Related]
16. Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors.
Kelly JJ; Barnes PJ; Giembycz MA
Br J Pharmacol; 1998 May; 124(1):129-40. PubMed ID: 9630352
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [3H]R-(-)-rolipram binding by selective inhibitors.
Kelly JJ; Barnes PJ; Giembycz MA
Biochem J; 1996 Sep; 318 ( Pt 2)(Pt 2):425-36. PubMed ID: 8809029
[TBL] [Abstract][Full Text] [Related]
18. Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram.
Xu RX; Rocque WJ; Lambert MH; Vanderwall DE; Luther MA; Nolte RT
J Mol Biol; 2004 Mar; 337(2):355-65. PubMed ID: 15003452
[TBL] [Abstract][Full Text] [Related]
19. Imaging of cAMP-specific phosphodiesterase-IV: comparison of [11C]rolipram and [11C]Ro 20-1724 in rats.
Lourenco CM; DaSilva JN; Warsh JJ; Wilson AA; Houle S
Synapse; 1999 Jan; 31(1):41-50. PubMed ID: 10025682
[TBL] [Abstract][Full Text] [Related]
20. Zinc dependent activation of cAMP-specific phosphodiesterase (PDE4A).
Percival MD; Yeh B; Falgueyret JP
Biochem Biophys Res Commun; 1997 Dec; 241(1):175-80. PubMed ID: 9405253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
